Sebetralstat: A Rapidly Acting Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema

Sebetralstat is a novel, potent, and selective oral plasma kallikrein inhibitor drug candidate in clinical development for the on-demand treatment of hereditary angioedema (HAE). Upon binding, sebetralstat induces a conformational change in the active site of plasma kallikrein, which contributes to...

Cijeli opis

Bibliografski detalji

Glavni autori:	Edward P. Feener, Rebecca L. Davie, Nivetha Murugesan, Stephen J. Pethen, Sally L. Hampton, Michael D. Smith, Paul K. Audhya, Chris M. Yea
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2024-04-01
Serija:	Drugs and Drug Candidates
Teme:	plasma kallikrein hereditary angioedema kallikrein kinin system bradykinin oral treatment plasma kallikrein inhibitor
Online pristup:	https://www.mdpi.com/2813-2998/3/2/19
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!